U.S., Jan. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07359859) titled 'A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant' on Jan. 21.
Brief Summary: The researchers are doing this study to compare 2 different GVHD prevention (prophylaxis) approaches. The researchers will see which approach is good or more effective at preventing chronic GVHD until 1 year after allogeneic hematopoietic stem cell transplantation (allo-HCT).
Study Start Date: Jan. 20
Study Type: INTERVENTIONAL
Condition:
Hematologic Malignancies
Intervention:
DRUG: Cyclophosphamide
An intermediate dose (medium dose) of Post-transplant Cycl...